Letters to the Editor

Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki
Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala
Department of Oncology and KG Jebsen center for B-cell malignancies, Oslo University Hospital, Oslo
Department of Hematology, Aarhus University Hospital, Aarhus
Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki
Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala
Department of Hematology, Aarhus University Hospital, Aarhus
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus
Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala
Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus
Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Medicine, division of clinical epidemiology, Karolinska Institutet, Solna
Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki
Haematologica Early view Mar 25, 2021 https://doi.org/10.3324/haematol.2020.278182